Enables fatty acid elongase activity. Involved in fatty acid elongation, polyunsaturated fatty acid and very long-chain fatty acid biosynthetic process. Predicted to be located in dendritic tree; endoplasmic reticulum; and neuronal cell body. Predicted to be active in endoplasmic reticulum membrane. Human ortholog(s) of this gene implicated in spinocerebellar ataxia type 38. Orthologous to human ELOVL5 (ELOVL fatty acid elongase 5); PARTICIPATES IN alpha-linolenic acid metabolic pathway; linoleic acid metabolic pathway; unsaturated fatty acid biosynthetic pathway; INTERACTS WITH 1-naphthyl isothiocyanate; 17beta-estradiol; 2,3,7,8-tetrachlorodibenzodioxine.
3-keto acyl-CoA synthase Elovl5; elongation of long chain fatty acids family member 5; elongation of very long chain fatty acids protein 5; elongation of very long chain fatty acids-like 5; ELOVL FA elongase 5; ELOVL family member 5, elongation of long chain fatty acids; ELOVL family member 5, elongation of long chain fatty acids (yeast); fatty acid elongase 1; rELO1; very long chain 3-ketoacyl-CoA synthase 5; very long chain 3-oxoacyl-CoA synthase 5; very long chain fatty acid elongase 5; very-long-chain 3-oxoacyl-CoA synthase 5
2-bromopalmitate inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of ELOVL5 protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ELOVL5 mRNA
2-bromopalmitate inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of ELOVL5 protein] and [Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of ELOVL5 protein
2-bromopalmitate inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of ELOVL5 protein] and [Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of ELOVL5 protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ELOVL5 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL5 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ELOVL5 mRNA
[perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of ELOVL5 mRNA and [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of ELOVL5 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL5 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL5 mRNA
(-)-Epigallocatechin-3-Gallate Ameliorates Atherosclerosis and Modulates Hepatic Lipid Metabolic Gene Expression in Apolipoprotein E Knockout Mice: Involvement of TTC39B.
